Thambisetty, Madhav;
Howard, Robert;
(2023)
Lecanemab trial in AD brings hope but requires greater clarity.
Nature Reviews Neurology
, 19
pp. 132-133.
10.1038/s41582-022-00768-w.
Preview |
Text
Howard_NRN_Lecanemab_MTRH.pdf Download (98kB) | Preview |
Abstract
The phase III Clarity AD clinical trial of lecanemab, an amyloid-targeting antibody, showed a small clinical beneft in people with Alzheimer disease. However, several questions remain regarding the true clinical relevance, safety and accessibility of lecanemab in this patient population
| Type: | Article |
|---|---|
| Title: | Lecanemab trial in AD brings hope but requires greater clarity |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41582-022-00768-w |
| Publisher version: | https://doi.org/10.1038/s41582-022-00768-w |
| Language: | English |
| Additional information: | This version is the author-accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry > Mental Health of Older People |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10169118 |
Downloads since deposit
526Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months
Archive Staff Only
 |
View Item |
